Low Molecular Weight Heparin in Preventing Perioperative Deep Venous Thrombosis in Breast Cancer Patients: a Prospective Randomized Controlled Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031537

Enrollment

Unknown

Registered

2020-04-03

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Experimental group:low molecular weight heparin

Control group:Blank

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Women over 18 years old; 2. Patients with breast cancer confirmed by preoperative pathology; 3. Patients without deep vein thrombosis of lower extremity detected by color Doppler ultrasound before operation; 4. Patients who can and are willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with previous history of VTE; 2. Patients with long-term anticoagulation; 3. Patients with thrombocytopenia (platelet count less than 100 x 10^9 platelets); 4. Patients with impaired renal function (serum creatinine > 180 µ mol / L or creatinine clearance < 30 ml / min); 5. Patients known to be allergic to heparin; 6. Patients with active bleeding or high bleeding risk diseases (gastric ulcer, brain malignant diseases); 7. Low weight patients, weight < 45kg; 8. Patients using NSAIDs; 9. Patients in other trials. 10. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Surgery time;Neoadjuvant chemotherapy or not;Age;BMI;	—

Countries

China

Contacts

Public ContactZhenggui Du

Department of Breast Surgery, West China Hospital of Sichuan University,

docduzg@163.com+86 18980605774

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026